Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  melphalan
Find trials that include:  Any drugs shown
Results 1-25 of 79 for your search:
Start Over
Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662
Melphalan with or without Busulfan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 2010-0071, NCI-2011-02760, cs2010-0032635MA, NCT01413178
Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Phase: Phase III
Type: Treatment
Age: 18 to 70
Trial IDs: 12338, NCI-2015-00185, 093270, 2012-0005534-11, NCT00491491, NCT02366663
Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A051301, NCI-2015-00668, BMT CTN 1201, NCT02443077
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C16011, NCI-2012-02752, 2011-005468-10, C16011-CTIL, NL41603.028.12, U1111-1164-7621, NCT01659658
Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: SOL-04058-L, NCI-2013-00786, 2868, CR00002456, OHSU-8507, OHSU-2868, OHSU-SOL-04058-L, NCT00303849
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients with Recurrent or Progressive CNS Embryonal or Germ Cell Tumors
Phase: Phase II, Phase I
Type: Treatment
Age: 1 to 30
Trial IDs: SOL-08131-L, NCI-2013-00790, 5056, MR00042551, OHSU-5056, NCT00983398
Lenalidomide, High-Dose Melphalan, and Autologous Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: IUCRO-0290, NCI-2010-01423, NCT01142232
Yttrium Y 90 Daclizumab and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with Recurrent or Refractory Hodgkin’s Lymphoma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-C-0003, NCI-2013-01512, 120003, P11859, NCT01468311
Umbilical Cord Blood-Derived Natural Killer Cells, Lenalidomide, High-Dose Melphalan, and Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: 2011-0379, NCI-2014-01096, NCI-2014-00541, RV-MM-PI-0691, NCT01729091
Carfilzomib and Melphalan before Stem Cell Transplant in Treating Patients with Multiple Myeloma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1185, NCI-2013-00550, NCT01842308
AP1903 and Genetically Modified Donor T Cells after Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 2012-0501, NCI-2013-01666, RM00000684-RN00, NCT01875237
Natural Killer Cells before and after Donor Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 2 to 65
Trial IDs: 2012-0708, NCI-2013-02183, 05-07-04832, P01 - 5P01, RP110553 05-07-04832, NCT01904136
Radiolabeled Monoclonal Antibody and Combination Chemotherapy before Stem Cell Transplant in Treating Patients with High-Risk Lymphoid Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2728.00, NCI-2013-01378, NCT01921387
Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients
Phase: Phase II, Phase I
Type: Treatment
Age: 45 and under
Trial IDs: NYMC 564, NCI-2015-01809, NCT02098512
Carfilzomib in Preventing Relapse and Graft-versus-Host Disease in Patients with High-Risk Hematologic Malignancies Undergoing Donor Hematopoietic Cell Transplant
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18 to less than 65
Trial IDs: UMCC 2014.010, NCI-2014-01923, 2014.010, CR00046767, HUM00084170, NCT02145403
Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 65
Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145
A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem Cell Transplant in AML Patients
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 75
Trial IDs: SGN33A-003, NCI-2015-02237, NCT02614560
Busulfan, Cyclophosphamide, and Melphalan in Treating Younger Patients With Juvenile Myelomonocytic Leukemia Undergoing Donor Hematopoietic Cell Transplant
Phase: Phase II
Type: Treatment
Age: 18 and under
Trial IDs: MT1999-20, NCI-2010-01703, 1999LS073, NCT00262756, NCT00167219
Busulfan, Melphalan, and Fludarabine Phosphate Followed by Donor Umbilical Cord Blood Transplant in Treating Younger Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome
Phase: Phase II
Type: Treatment
Age: 2 and under at diagnosis
Trial IDs: MT2005-25, NCI-2010-02159, 2005LS075, UMN-2005LS075, UMN-MT2005-25, UMN-0511M77206, NCT00357565
Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma
Phase: Phase II
Type: Treatment
Age: 18 to 70
Trial IDs: 201101864, NCI-2011-00728, 09-0042, NCT00882895
High-Dose Chemotherapy, Bevacizumab and Stem Cell Transplant in Treating Patients with Recurrent Germ Cell Tumors
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2008-0378, NCI-2011-01631, NCT00936936
Start Over